Overview

A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise

Status:
Withdrawn
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate that the combination of inhaled fluticasone furoate/vilanterol (100 mcg/25 mcg) once daily provides superior protection throughout the day against bronchoconstriction induced by exercise compared with fluticasone propionate 250 mcg twice daily in adolescent and adult subjects aged 12 to 50 diagnosed with persistent asthma.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone
Xhance